Abstract
Increasing evidence supports the view that oxidative stress and brain demyelination play an important role in the pathogenesis of schizophrenia. Resveratrol is a powerful antioxidant with neuroprotective effects. This study aimed to assess the effect of resveratrol on schizophrenia-like behaviors and possible brain demyelination induced by MK-801, an N-methyl-D-aspartate glutamate receptor antagonist, and the underlying neuroprotective mechanism. Resveratrol (40 mg/kg/day/, intraperitoneal) was administered to mice for 14 days. MK-801 (1 mg/kg/day, intraperitoneal) was injected into the mice 4 h after the resveratrol administration for 14 days. The open-field and elevated-plus maze tests were performed to detect behavior changes on the 15th day. Following the behavioral tests, the expression of the myelin basic protein (MBP) was measured with the real-time PCR (RT-PCR) method, while total oxidant capacity (TOS) and total antioxidant capacity (TAS), which are the biomarkers of oxidative damage, were measured with the ELISA method. Hematoxylin-eosin staining was also used to identify stereological and pathological changes in the brain. According to the results obtained, this study showed for the first time that resveratrol prevented glial cell infiltration induced in the brain by MK-801 and shrinkage of nerve cell nuclei in the hippocampus and corpus callosum. However, the resveratrol administrations did not correct behavioral disorders and demyelination of schizophrenia. Although resveratrol partially prevented oxidative damage in the brain in the mice that were injected with MK-801, it was determined that this effect was not statistically significant. These results showed that resveratrol administration partially protects tissues against MK-801-induced neurodegeneration, and resveratrol may be used in combination with different antioxidants or at different doses in future studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
The datasets used/analyzed in this study are available from the corresponding author on reasonable request.
References
Abdel-Daim MM, Eissa IAM, Abdeen A, Abdel-Latif HMR, Ismail M, Dawood MAO, Hassan AM (2019) Lycopene and resveratrol ameliorate zinc oxide nanoparticles-induced oxidative stress in Nile tilapia, Oreochromis niloticus. Environ Toxicol Pharmacol 69:44–50. https://doi.org/10.1016/j.etap.2019.03.016
Ahmed HI, Abdel-Sattar SA, Zaky HS (2018) Vinpocetine halts ketamine-induced schizophrenia-like deficits in rats: impact on BDNF and GSK-3β/β-catenin pathway. Naunyn Schmiedeberg's Arch Pharmacol 391:1327–1338. https://doi.org/10.1007/s00210-018-1552-y
Akillioglu K, Babar Melik E, Melik E, Kocahan S (2012a) The investigation of neonatal MK-801 administration and physical environmental enrichment on emotional and cognitive functions in adult Balb/c mice. Pharmacol Biochem Behav 102:407–414. https://doi.org/10.1016/j.pbb.2012.06.006
Akillioglu K, Binokay S, Kocahan S (2012b) The effect of neonatal N-methyl-D-aspartate receptor blockade on exploratory and anxiety-like behaviors in adult BALB/c and C57BL/6 mice. Behav Brain Res 233:157–161
Akter R, Rahman MH, Behl T, Chowdhury MAR, Manirujjaman M, Bulbul IJ, Elshenaw SE, Tit DM, Bungau S (2021) Prospective role of polyphenolic compounds in the treatment of neurodegenerative diseases. CNS Neurol Disord Drug Targets 20. https://doi.org/10.2174/1871527320666210218084444
Al Basher G, Abdel-Daim MM, Almeer R, Ibrahim KA, Hamza RZ, Bungau S, Aleya L (2020) Synergistic antioxidant effects of resveratrol and curcumin against fipronil-triggered oxidative damage in male albino rats. Environ Sci Pollut Res 27:6505–6514. https://doi.org/10.1007/s11356-019-07344-8
Amani M, Samadi H, Doosti MH, Azarfarin M, Bakhtiari A, Majidi-Zolbanin N, Mirza-Rahimi M, Salari AA (2013) Neonatal NMDA receptor blockade alters anxiety- and depression-related behaviors in a sex-dependent manner in mice. Neuropharmacology 73:87–97. https://doi.org/10.1016/j.neuropharm.2013.04.056
Andrabi SS, Vishnoi S, Kaushik M, Parveen K, Tabassum H, Akram M, Parvez S (2019) Reversal of schizophrenia-like symptoms and cholinergic alterations by melatonin. Arch Med Res 50:295–303. https://doi.org/10.1016/j.arcmed.2019.08.005
Le Bai Z, Li XS, Chen GY et al (2018) Serum oxidative stress marker levels in unmedicated and medicated patients with schizophrenia. J Mol Neurosci 66:428–436. https://doi.org/10.1007/s12031-018-1165-4
Balu DT (2016) The NMDA Receptor and schizophrenia: from pathophysiology to treatment. Adv Pharmacol 76:351–382. https://doi.org/10.1016/bs.apha.2016.01.006
Baser O, Xie L, Pesa J, Durkin M (2015) Healthcare utilization and costs of veterans health administration patients with schizophrenia treated with paliperidone palmitate long-acting injection or oral atypical antipsychotics. J Med Econ 18:357–365. https://doi.org/10.3111/13696998.2014.1001514
Bitanihirwe BKY, Woo TUW (2011) Oxidative stress in schizophrenia: an integrated approach. Neurosci Biobehav Rev 35:878–893
De Hert M, Detraux J, Van Winkel R et al (2012) Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol 8:114–126
Du X, Kätzel D, Kim J-I et al (2019) NMDAR hypofunction animal models of schizophrenia. NMDAR Hypofunction Anim Model Schizophr. Front Mol Neurosci 12:185. https://doi.org/10.3389/fnmol.2019.00185
Erel O (2005) A new automated colorimetric method for measuring total oxidant status. Clin Biochem 38:1103–1111. https://doi.org/10.1016/j.clinbiochem.2005.08.008
Erel O (2004) A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clin Biochem 37:277–285. https://doi.org/10.1016/j.clinbiochem.2003.11.015
Fix AS, Ross JF, Stitzel SR, Switzer RC (1996) Integrated evaluation of central nervous system lesions: stains for neurons, astrocytes, and microglia reveal the spatial and temporal features of MK-801-induced neuronal necrosis in the rat cerebral cortex. Toxicol Pathol 24:291–304. https://doi.org/10.1177/019262339602400305
Flatow J, Buckley P, Miller BJ (2013) Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 74:400–409. https://doi.org/10.1016/j.biopsych.2013.03.018
Flynn SW, Lang DJ, Mackay AL, Goghari V, Vavasour IM, Whittall KP, Smith GN, Arango V, Mann JJ, Dwork AJ, Falkai P, Honer WG (2003) Abnormalities of myelination in schizophrenia detected in vivo with MRI, and post-mortem with analysis of oligodendrocyte proteins. Mol Psychiatry 8:811–820. https://doi.org/10.1038/sj.mp.4001337
Fodor K, Tit DM, Pasca B, Bustea C, Uivarosan D, Endres L, Iovan C, Abdel-Daim MM, Bungau S (2018) Long-term resveratrol supplementation as a secondary prophylaxis for stroke. Oxidative Med Cell Longev 2018:1–10. https://doi.org/10.1155/2018/4147320
Gallo V, Patneau DK, Mayer ML, Vaccarino FM (1994) Excitatory amino acid receptors in glial progenitor cells: molecular and functional properties. Glia 11:94–101. https://doi.org/10.1002/glia.440110204
Gama CS, Salvador M, Andreazza AC, Kapczinski F, Silva Belmonte-de-Abreu P (2006) Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in schizophrenia: a study of patients treated with haloperidol or clozapine. Prog Neuro-Psychopharmacol Biol Psychiatry 30:512–515. https://doi.org/10.1016/j.pnpbp.2005.11.009
Garba Magaji M, Oghenekome Iniaghe L, Abolarin M et al (2017) Neurobehavioural evaluation of resveratrol in murine models of anxiety and schizophrenia. Metab Brain Dis 32:437–442. https://doi.org/10.1007/s11011-016-9927-6
Ghaiad HR, Nooh MM, El-Sawalhi MM, Shaheen AA (2017) Resveratrol promotes remyelination in cuprizone model of multiple sclerosis: biochemical and histological study. Mol Neurobiol 54:3219–3229. https://doi.org/10.1007/s12035-016-9891-5
Gu Z, Chu L, Han Y (2019) Therapeutic effect of resveratrol on mice with depression. Exp Ther Med 17:3061–3064. https://doi.org/10.3892/etm.2019.7311
Gundersen HJG, Bendtsen TF, Korbo L et al (1988) Some new, simple and efficient stereological methods and their use in pathological research and diagnosis. APMIS 96:379–394
Hasan Tahsin Kilic O, Aksoy I, Cinpolat Elboga G, Bulbul F (2019) Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients. Oxidative parameters, oxidative DNA damage, and urotensin-II in schizoaffective disorder patients. Psychiatry Clin Psychopharmacol 29:151–157. https://doi.org/10.1080/24750573.2018.1468637
He J, Zu Q, Wen C, Liu Q, You P, Li X, Wang W (2020) Quetiapine attenuates schizophrenia-like behaviors and demyelination in a MK-801—induced mouse model of schizophrenia. Article 11:1. https://doi.org/10.3389/fpsyt.2020.00843
Hereta M, Kamińska K, Rogóż Z (2019) Co-treatment with antidepressants and aripiprazole reversed the MK-801-induced some negative symptoms of schizophrenia in rats. Pharmacol Rep 71:768–773. https://doi.org/10.1016/j.pharep.2019.04.007
Hurley LL, Akinfiresoye L, Kalejaiye O, Tizabi Y (2014) Antidepressant effects of resveratrol in an animal model of depression. Behav Brain Res 268:1–7. https://doi.org/10.1016/j.bbr.2014.03.052
Ibrahim A, Al-Hizab FA, Abushouk AI, Abdel-Daim MM (2018) Nephroprotective effects of benzyl ısothiocyanate and resveratrol against cisplatin-ınduced oxidative stress and ınflammation. Front Pharmacol 9:1268. https://doi.org/10.3389/fphar.2018.01268
Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, Jenner P, Halliwell B (1995) Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochem Pharmacol 49:359–365. https://doi.org/10.1016/0006-2952(94)00424-K
Ke T, Li R, Chen W (2016) Inhibition of the NMDA receptor protects the rat sciatic nerve against ischemia/reperfusion injury. Exp Ther Med 11:1563–1572. https://doi.org/10.3892/etm.2016.3148
Lee SH, Kubicki M, Asami T, Seidman LJ, Goldstein JM, Mesholam-Gately RI, McCarley RW, Shenton ME (2013) Extensive white matter abnormalities in patients with first-episode schizophrenia: a diffusion tensor imaging (DTI) study. Schizophr Res 143:231–238. https://doi.org/10.1016/j.schres.2012.11.029
Lim AL, Taylor DA, Malone DT (2012) A two-hit model: behavioural investigation of the effect of combined neonatal MK-801 administration and isolation rearing in the rat. J Psychopharmacol 26:1252–1264. https://doi.org/10.1177/0269881111430751
Luo C, Wang X, Mao X, Huang H, Liu Y, Zhao J, Zhou H, Liu Z, Li X (2020) Metformin attenuates antipsychotic-induced metabolic dysfunctions in MK801-induced schizophrenia-like rats. Psychopharmacology 237:2257–2277. https://doi.org/10.1007/s00213-020-05524-w/Published
Maas DA, Vallès A, Martens GJM (2017) Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl Psychiatry 7:e1171
Madireddy S, Madireddy S (2020) Regulation of reactive oxygen species-mediated damage in the pathogenesis of schizophrenia. Brain Sci 10:742. https://doi.org/10.3390/brainsci10100742
Makkar R, Behl T, Bungau S, Zengin G, Mehta V, Kumar A, Uddin MS, Ashraf GM, Abdel-Daim MM, Arora S, Oancea R (2020) Nutraceuticals in neurological disorders. Int J Mol Sci 21:1–19. https://doi.org/10.3390/ijms21124424
Mutlu O, Ulak G, Celikyurt IK, Akar FY, Erden F, Tanyeri P (2011) Effects of olanzapine, sertindole and clozapine on MK-801 induced visual memory deficits in mice. Pharmacol Biochem Behav 99:557–565. https://doi.org/10.1016/j.pbb.2011.06.011
Niu J, Cao Y, Ji Y (2020) Resveratrol, a SIRT1 activator, ameliorates MK-801-ınduced cognitive and motor ımpairments in a neonatal rat model of schizophrenia. Front Psychiatry 11:716. https://doi.org/10.3389/fpsyt.2020.00716
O’Donnell P, Do KQ, Arango C (2014) Oxidative/nitrosative stress in psychiatric disorders: are we there yet? Schizophr Bull 40:960–962. https://doi.org/10.1093/schbul/sbu048
Olney JW, Labruyere J, Price MT (1989) Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science (80-) 244:1360–1362. https://doi.org/10.1126/science.2660263
Orlovskaya DD, Denisov DV, Uranova NA (1997) The ultrastrucfural pathology of myelinated fibers and oligodendroglial cells in autopsied caudate nucleus of schizophrenics. Schizophr Res 24:39–40. https://doi.org/10.1016/s0920-9964(97)82111-1
Orrico-Sánchez A, López-Lacort M, Muñoz-Quiles C, Sanfélix-Gimeno G, Díez-Domingo J (2020) Epidemiology of schizophrenia and its management over 8-years period using real-world data in Spain. BMC Psychiatry 20:149. https://doi.org/10.1186/s12888-020-02538-8
Ozyurt B, Ozyurt H, Akpolat N, Erdogan H, Sarsilmaz M (2007a) Oxidative stress in prefrontal cortex of rat exposed to MK-801 and protective effects of CAPE. Prog Neuro-Psychopharmacol Biol Psychiatry 31:832–838
Ozyurt B, Sarsilmaz M, Akpolat N, Ozyurt H, Akyol O, Herken H, Kus I (2007b) The protective effects of omega - 3 fatty acids against MK-801-induced neurotoxicity in prefrontal cortex of rat. Neurochem Int 50:196–202. https://doi.org/10.1016/j.neuint.2006.08.002
Ozyurt H, Ozyurt B, Sarsilmaz M et al (2014) Potential role of some oxidant/antioxidant status parameters in prefrontal cortex of rat brain in an experimental psychosis model and the protective effects of melatonin. Eur Rev Med Pharmacol Sci 18:2137–2144
Pinar N, Akillioglu K, Sefil F et al (2015) Effect of clozapine on locomotor activity and anxiety-related behavior in the neonatal mice administered MK-801. Bosn J Basic Med Sci 15:74–79. https://doi.org/10.17305/bjbms.2015.472
Rahman MH, Akter R, Bhattacharya T, Abdel-Daim MM, Alkahtani S, Arafah MW, al-Johani NS, Alhoshani NM, Alkeraishan N, Alhenaky A, Abd-Elkader OH, el-Seedi HR, Kaushik D, Mittal V (2020a) Resveratrol and neuroprotection: ımpact and ıts therapeutic potential in Alzheimer’s disease. Front Pharmacol 11:619024. https://doi.org/10.3389/fphar.2020.619024
Rahman MH, Akter R, Kamal MA (2020b) Prospective function of different antioxidant containing natural products in the treatment of neurodegenerative disease. CNS Neurol Disord Drug Targets 19. https://doi.org/10.2174/1871527319666200722153611
Rogóż Z, Wąsik A, Lorenc-Koci E (2018) Combined treatment with aripiprazole and antidepressants reversed some MK-801-induced schizophrenia-like symptoms in mice. Pharmacol Rep 70:623–630. https://doi.org/10.1016/j.pharep.2018.02.022
Rossetti AC, Paladini MS, Riva MA, Molteni R (2020) Oxidation-reduction mechanisms in psychiatric disorders: a novel target for pharmacological intervention. Pharmacol Ther 210:107520
Sato F, Martinez NE, Shahid M, Rose JW, Carlson NG, Tsunoda I (2013) Resveratrol exacerbates both autoimmune and viral models of multiple sclerosis. Am J Pathol 183:1390–1396. https://doi.org/10.1016/j.ajpath.2013.07.006
Shaito A, Posadino AM, Younes N, Hasan H, Halabi S, Alhababi D, al-Mohannadi A, Abdel-Rahman WM, Eid AH, Nasrallah GK, Pintus G (2020) Potential adverse effects of resveratrol: a literature review. Int J Mol Sci 21:2084. https://doi.org/10.3390/ijms21062084
Shayganfard M (2020) Molecular and biological functions of resveratrol in psychiatric disorders: a review of recent evidence. Cell Biosci 10:1–14
Taksande BG, Kotagale NR, Tripathi SJ, Ugale RR, Chopde CT (2009) Antidepressant like effect of selective serotonin reuptake inhibitors involve modulation of imidazoline receptors by agmatine. Neuropharmacology 57:415–424. https://doi.org/10.1016/j.neuropharm.2009.06.035
Ueno H, Shimada A, Suemitsu S, Murakami S, Kitamura N, Wani K, Matsumoto Y, Okamoto M, Ishihara T (2019) Attenuation effects of alpha-pinene ınhalation on mice with dizocilpine-ınduced psychiatric-like behaviour. Evid-based Complement Altern Med 2019:12. https://doi.org/10.1155/2019/2745453
Unal G, Sirvanci S, Aricioglu F (2021) α7 nicotinic receptor agonist and positive allosteric modulators differently improved schizophrenia-like cognitive deficits in male rats. Behav Brain Res 397:112946. https://doi.org/10.1016/j.bbr.2020.112946
Uno Y, Coyle JT (2019) Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci 73:204–215. https://doi.org/10.1111/pcn.12823
Upaganlawar AB, Uddin S, Upasani CD (2021) Bioactive nutraceuticals for brain disorders. Nova Science Publishers, New York
Uranova N, Orlovskaia D, Vikhreva O et al (2001) Morphometric study of ultrastructural changes in oligodendroglial cells in the postmortem brain in endogenous psychoses. Vestn Ross Akad Med Nauk 7:42–48
Vestergaard M, Ingmer H (2019) Antibacterial and antifungal properties of resveratrol. Int J Antimicrob Agents 53:716–723
Wang Q, Xu J, Rottinghaus GE, Simonyi A, Lubahn D, Sun GY, Sun AY (2002) Resveratrol protects against global cerebral ischemic injury in gerbils. Brain Res 958:439–447. https://doi.org/10.1016/S0006-8993(02)03543-6
Wei Xin Chong J, Hsien-Jie Tan E, Chong CE, Ng Y, Wijesinghe R (2016) Atypical antipsychotics: a review on the prevalence, monitoring, and management of their metabolic and cardiovascular side effects. Ment Heal Clin 6:178–184. https://doi.org/10.9740/mhc.2016.07.178
WHO (2019) Schizophrenia
Xiu Y, Kong X-R, Zhang L, Qiu X, Chao FL, Peng C, Gao Y, Huang CX, Wang SR, Tang Y (2014) White matter ınjuries ınduced by MK-801 in a mouse model of schizophrenia based on NMDA antagonism. Anat Rec 297:1498–1507. https://doi.org/10.1002/ar.22942
Xiu Y, Ru KX, Zhang L et al (2015) The myelinated fiber loss in the corpus callosum of mouse model of schizophrenia induced by MK-801. J Psychiatr Res 63:132–140. https://doi.org/10.1016/j.jpsychires.2015.02.013
Yeung AWK, Tzvetkov NT, El-Tawil OS et al (2019) Antioxidants: scientific literature landscape analysis. Oxidative Med Cell Longev 2019:1–11. https://doi.org/10.1155/2019/8278454
Yi NX, Zhou LY, Wang XY, Song YJ, Han HH, Zhang TS, Wang YJ, Shi Q, Xu H, Liang QQ, Zhang T (2019) MK-801 attenuates lesion expansion following acute brain injury in rats: a meta-analysis. Neural Regen Res 14:1919–1931. https://doi.org/10.4103/1673-5374.259619
Zhang R, He J, Zhu S, Zhang H, Wang H, Adilijiang A, Kong L, Wang J, Kong J, Tan Q, Li XM (2012) Myelination deficit in a phencyclidine-induced neurodevelopmental model of schizophrenia. Brain Res 1469:136–143. https://doi.org/10.1016/j.brainres.2012.06.003
Zortea K, Franco VC, Guimarães P, Belmonte-de-Abreu PS (2016) Resveratrol supplementation did not ımprove cognition in patients with schizophrenia: results from a randomized clinical trial. Front Psychiatry 7:16. https://doi.org/10.3389/fpsyt.2016.00159
Funding
This study was financially supported by the Scientific Research Project Coordination Unit at Afyon Kocatepe University (16.Kariyer.130).
Author information
Authors and Affiliations
Contributions
The idea of the research was recommended by M.S.A, who also took part in the design of the study. M.S.A. and R.T. performed the experimental work and wrote/drafted/edited the manuscript, and interpreted the results. M.S.A., R.T., and H.H.D. performed the laboratory analyses. All authors were involved in revising the manuscript critically for important intellectual content, and all authors approved the final version to be published.
Corresponding author
Ethics declarations
Ethics approval
The Animal Experiments Local Ethics Board, Afyon Kocatepe University, Afyon, (Registration number: AKUHADYEK-132-16) has approved this study.
Consent to participate
Not applicable.
Consent for publication
Not applicable.
Conflict of interest
The authors declare no competing interests.
Additional information
Responsible Editor: Mohamed M. Abdel-Daim
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Akosman, .S., Türkmen, R. & Demirel, H.H. Investigation of the protective effect of resveratrol in an MK-801-induced mouse model of schizophrenia. Environ Sci Pollut Res 28, 65872–65884 (2021). https://doi.org/10.1007/s11356-021-15664-x
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11356-021-15664-x